Skip to main content

Apellis Pharmaceuticals, Inc.

APLSDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001492422

Apellis Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Apellis Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Apellis Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Apellis Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Wheeler Craig ADirector0May 14, 20262
Dolsten MikaelDirector0May 14, 20262
Machiels AlecDirector0May 14, 20262
Chan GeraldDirector0May 14, 20262
Watson David O.General Counsel0May 14, 20269
Deschatelets PascalChief Scientific Officer0May 14, 20265
Francois CedricChief Executive Officer0May 14, 20267
Sullivan Timothy EugeneChief Financial Officer0May 14, 20267
O'Brien Stephanie MonaghanDirector0May 14, 20263
Dunlop A. SinclairDirector0May 14, 20264
Fonteyne Paul R.Director0May 14, 20262
Nicholson NurChief Technical Officer0May 14, 20265
Chopas James GeorgeVP/Chief Accounting Officer0May 14, 20265
DeLong Mark JeffreyChief Business & Strat Officer0May 14, 20266
Baumal CarolineChief Medical Officer0May 14, 20265
Walbert KeliDirector0May 14, 20262
Boucher KelleyChief People Officer0May 14, 20262
Meltzer LeslieChief Research and Development0May 14, 20262
Townsend Adam J.Chief Commercial Officer84,050Jan 30, 20250
Lewis KarenChief People Officer70,251Jan 30, 20250
Eisele JeffreyChief Development Officer55,312Jan 30, 20250
Scheibler LukasChief Research Officer68,299Dec 5, 20230
Brown Victoria L.Program Team Lead23,556Jan 24, 20230
Grossi FedericoChief Medical Officer94,884Jan 9, 20230
Morningside Venture Investments Ltd10% Owner12,806,342Nov 18, 20210
Perry Nicole DVice President - Accounting4,847Aug 3, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 21, 2023 (view filing)Feb 174 daysMachiels AlecDirectorSSale−1.25K$52.38−$65.5K−0.5%267.6K after
Feb 27, 2023 (view filing)Feb 234 daysLewis KarenChief People OfficerSSale−1.10K$68.76−$75.9K−2.6%41.4K after
Feb 27, 2023 (view filing)Feb 234 daysEisele JeffreyChief Development OfficerSSale−1.65K$68.76−$113.2K−3.0%53.9K after
Mar 2, 2023 (view filing)Mar 11 dayDunlop A. SinclairDirectorSSale−500$65.33−$32.7K−0.4%131.8K after
Mar 7, 2023 (view filing)Mar 34 daysTownsend Adam J.Chief Commercial OfficerSSale−5.00K$63.84−$319.2K−6.2%76.0K after
Mar 10, 2023 (view filing)Mar 82 daysDeschatelets PascalChief Scientific OfficerSSale−12.0K$63.79−$765.5K−1.2%1.02M after
Mar 21, 2023 (view filing)Mar 174 daysMachiels AlecDirectorSSale−1.25K$64.03−$80.0K−0.5%267.6K after
Mar 23, 2023 (view filing)Mar 212 daysFrancois CedricChief Executive OfficerSSale−30.0K$62.74−$1.88M−2.6%1.14M after
Apr 5, 2023 (view filing)Apr 32 daysTownsend Adam J.Chief Commercial OfficerSSale−5.00K$74.05−$370.3K−6.2%76.0K after10b5-1
Apr 5, 2023 (view filing)Apr 32 daysLewis KarenChief People OfficerSSale−5.00K$75.00−$375.0K−10.8%41.4K after10b5-1
Apr 5, 2023 (view filing)Apr 32 daysDunlop A. SinclairDirectorSSale−500$74.05−$37.0K−0.4%131.3K after10b5-1
Apr 11, 2023 (view filing)Apr 101 dayDeschatelets PascalChief Scientific OfficerSSale−12.0K$78.21−$938.5K−1.2%1.03M after10b5-1
Apr 18, 2023 (view filing)Apr 171 dayMachiels AlecDirectorSSale−1.25K$81.05−$101.3K−0.5%267.6K after10b5-1
Apr 20, 2023 (view filing)Apr 182 daysFrancois CedricChief Executive OfficerSSale−30.0K$82.02−$2.46M−4.5%637.6K after10b5-1
May 4, 2023 (view filing)May 31 dayTownsend Adam J.Chief Commercial OfficerSSale−5.00K$82.71−$413.6K−6.2%76.0K after10b5-1
May 9, 2023 (view filing)May 81 dayDeschatelets PascalChief Scientific OfficerSSale−12.0K$92.39−$1.11M−1.1%1.03M after10b5-1
May 18, 2023 (view filing)May 162 daysFrancois CedricChief Executive OfficerSSale−30.0K$85.66−$2.57M−9.8%274.7K after6 lots
May 18, 2023 (view filing)May 171 dayMachiels AlecDirectorSSale−1.25K$88.66−$110.8K−0.5%267.6K after10b5-1
Jun 2, 2023 (view filing)Jun 11 dayLewis KarenChief People OfficerSSale−5.00K$86.00−$430.0K−10.8%41.5K after10b5-1
Jun 6, 2023 (view filing)Jun 51 daySullivan Timothy EugeneChief Financial OfficerSSale−69.8K$88.80−$6.20M−47.3%77.7K after4 lots10b5-1
Jun 9, 2023 (view filing)Jun 81 dayDeschatelets PascalChief Scientific OfficerSSale−12.0K$91.35−$1.10M−1.1%1.04M after10b5-1
Jun 21, 2023 (view filing)Jun 201 dayMachiels AlecDirectorSSale−1.25K$88.41−$110.5K−0.5%267.6K after10b5-1
Jul 6, 2023 (view filing)Jul 33 daysSullivan Timothy EugeneChief Financial OfficerSSale−6.78K$89.97−$609.9K−8.0%77.7K after3 lots10b5-1
Jul 6, 2023 (view filing)Jul 33 daysWatson David O.General CounselSSale−8.51K$89.98−$765.7K−9.0%85.8K after10b5-1
Jul 11, 2023 (view filing)Jul 101 dayDeschatelets PascalChief Scientific OfficerSSale−12.0K$84.55−$1.01M−1.1%1.05M after10b5-1
Jul 18, 2023 (view filing)Jul 171 dayMachiels AlecDirectorSSale−1.25K$64.79−$81.0K−0.5%267.6K after10b5-1
Aug 9, 2023 (view filing)Aug 81 dayDeschatelets PascalChief Scientific OfficerSSale−12.0K$23.66−$283.9K−1.1%1.05M after10b5-1
Sep 1, 2023 (view filing)Sep 1Same dayFrancois CedricChief Executive OfficerSSale−150.0K$41.75−$6.26M−26.1%424.7K after2 lots
Sep 1, 2023 (view filing)Aug 311 dayChopas James GeorgeVP/Chief Accounting OfficerSSale−551$41.23−$22.7K−1.8%30.3K after
Sep 7, 2023 (view filing)Sep 61 dayScheibler LukasChief Research OfficerSSale−1.76K$43.01−$75.5K−2.5%68.3K after
Sep 11, 2023 (view filing)Sep 83 daysDeschatelets PascalChief Scientific OfficerSSale−12.0K$42.87−$514.4K−1.1%1.06M after10b5-1
Sep 18, 2023 (view filing)Sep 153 daysMachiels AlecDirectorSSale−1.25K$45.34−$56.7K−0.3%367.4K after10b5-1
Sep 19, 2023 (view filing)Sep 181 dayNicholson NurChief Technical OfficerSSale−20.4K$44.27−$900.9K−27.6%53.3K after2 lots
Sep 19, 2023 (view filing)Sep 181 dayMachiels AlecDirectorSSale−1.25K$45.00−$56.3K−0.3%367.4K after10b5-1
Oct 10, 2023 (view filing)Oct 91 dayDeschatelets PascalChief Scientific OfficerSSale−12.0K$40.38−$484.6K−1.1%1.07M after10b5-1
Oct 18, 2023 (view filing)Oct 171 dayMachiels AlecDirectorSSale−1.25K$48.50−$60.6K−0.3%367.4K after10b5-1
Oct 24, 2023 (view filing)Oct 231 dayDeLong Mark JeffreyChief Business & Strat OfficerSSale−131$46.04−$6.03K−0.3%51.6K after
Oct 24, 2023 (view filing)Oct 231 dayChopas James GeorgeVP/Chief Accounting OfficerSSale−132$46.04−$6.08K−0.4%32.7K after
Nov 9, 2023 (view filing)Nov 81 dayDeschatelets PascalChief Scientific OfficerSSale−12.0K$47.27−$567.2K−1.1%1.07M after10b5-1
Nov 20, 2023 (view filing)Nov 173 daysMachiels AlecDirectorSSale−1.25K$47.74−$59.7K−0.3%367.4K after10b5-1
Nov 21, 2023 (view filing)Oct 1735 daysLateDunlop A. SinclairDirectorSSale−24.0K$49.00−$1.18M−10.0%216.7K after
Nov 21, 2023 (view filing)Nov 21Same dayFrancois CedricChief Executive OfficerSSale−5.00K$48.80−$244.0K−1.8%269.7K after
Nov 21, 2023 (view filing)Nov 174 daysDunlop A. SinclairDirectorSSale−8.89K$49.99−$444.6K−6.8%122.4K after
Dec 1, 2023 (view filing)Nov 301 daySullivan Timothy EugeneChief Financial OfficerSSale−14.2K$54.73−$774.9K−15.4%77.7K after2 lots10b5-1
Dec 5, 2023 (view filing)Dec 14 daysDunlop A. SinclairDirectorSSale−24.0K$61.14−$1.47M−11.1%192.7K after
Dec 5, 2023 (view filing)Dec 14 daysTownsend Adam J.Chief Commercial OfficerSSale−110.0K$60.81−$6.69M−59.0%76.4K after2 lots10b5-1
Dec 5, 2023 (view filing)Dec 14 daysScheibler LukasChief Research OfficerSSale−10.0K$60.00−$600.0K−12.8%68.3K after10b5-1
Dec 20, 2023 (view filing)Dec 191 dayWatson David O.General CounselSSale−3.90K$57.22−$223.5K−4.2%89.8K after2 lots
Dec 28, 2023 (view filing)Dec 26-272 daysEisele JeffreyChief Development OfficerSSale−303$59.70−$18.1K−0.6%53.6K after2 lots10b5-1
Jan 5, 2024 (view filing)Jan 41 dayBaumal CarolineChief Medical OfficerSSale−2.75K$60.05−$165.2K−7.7%32.9K after